Literature DB >> 7114136

Cataracts associated with allopurinol therapy.

F T Fraunfelder, C Hanna, M W Dreis, K W Cosgrove.   

Abstract

The National Registry of Drug-Induced Ocular Side Effects has accumulated 30 cases of suspected allopurinol-induced lens changes. The cataracts associated with this antihyperuricemic agent are initially anterior and posterior lens capsule changes with anterior subcapsular vacuoles. With time, wedge-shaped anterior and posterior cortical haze occurs, along with dense posterior subcapsular cataracts. Histologic studies of these cataracts showed no unique or identifying features. These cases do not prove a cause-and-effect relationship, but raise the suspicion that allopurinol may be cataractogenic in some patients. Additional case reports and lens material should be sent to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Rd., Portland, OR 97201.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114136     DOI: 10.1016/0002-9394(82)90067-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Allopurinol use and the risk of cataract formation.

Authors:  W K Clair; L T Chylack; E F Cook; L Goldman
Journal:  Br J Ophthalmol       Date:  1989-03       Impact factor: 4.638

Review 2.  Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia.

Authors:  Yael Sharon; Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  Aetiology of congenital and paediatric cataract in an Australian population.

Authors:  M G Wirth; I M Russell-Eggitt; J E Craig; J E Elder; D A Mackey
Journal:  Br J Ophthalmol       Date:  2002-07       Impact factor: 4.638

4.  The association between gout and cataract risk: A meta-analysis.

Authors:  Chenqi Luo; Xinyi Chen; Hongchuan Jin; Ke Yao
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.